Compass Pathways Plc Stock Price, News & Analysis

COMPASS Pathways plc (CMPS) has announced positive results from a phase I study on COMP360 psilocybin therapy, demonstrating its feasibility in simultaneous administration to healthy participants under 1:1 therapist support. Conducted by King's College London, the study involved 89 participants receiving different doses of psilocybin or placebo, with no serious adverse effects reported. The findings suggest potential for psilocybin therapy in treating severe mental health issues, paving the way for upcoming FDA discussions and plans for a phase III trial expected to begin in Q3 2022.

COMPASS Pathways (Nasdaq: CMPS) announced its addition to the Nasdaq Biotechnology Index, effective December 20, 2021. This index tracks biotech and pharmaceutical securities, making it significant for institutional investors. CEO George Goldsmith expressed pride in this achievement, which aims to enhance visibility as the company advances its COMP360 psilocybin therapy for mental health. This therapy has received FDA Breakthrough Therapy designation for treatment-resistant depression and has shown statistically significant clinical trial results.

COMPASS Pathways (Nasdaq: CMPS) has appointed Matthew Owens as its new General Counsel and Chief Legal Officer, effective February 1, 2022. Owens joins from Novartis, where he was the Global Head of Legal, Digital. Concurrently, Lars Wilde, co-founder and Chief Business Officer, will transition to a senior advisory role from January 1, 2022. Under Wilde's leadership, COMPASS raised over $429 million and advanced its psilocybin therapy for mental health, which has received Breakthrough Therapy designation from the FDA.

COMPASS Pathways (Nasdaq: CMPS) announced positive results from its study of COMP360 psilocybin therapy in patients concurrently taking SSRIs. In this phase IIb trial, 19 patients treated with a 25mg dose had comparable outcomes to those who discontinued SSRIs before treatment. 42.1% of participants responded after three weeks, with an average MADRS score reduction of 14.9. Notably, no serious adverse events emerged. COMPASS is now preparing to meet with the FDA to finalize its phase III program planned to start in Q3 2022.

COMPASS Pathways plc (Nasdaq: CMPS) announced the appointment of Michael Falvey as Chief Financial Officer, effective January 1, 2022. He replaces Piers Morgan, who departs at year-end. Falvey has a robust background in finance, having previously led financial strategies at Karyopharm Therapeutics and other growth companies. His expertise will be vital as COMPASS advances its psilocybin therapy for treatment-resistant depression, especially following recent positive Phase IIb clinical trial results. The company has raised over $425 million and aims to transform mental health care.

COMPASS Pathways (Nasdaq: CMPS) announced positive results from its phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD). Additional analyses validated prior findings, showing significant improvements in depression symptoms and overall patient functioning with a 25mg dose compared to 1mg. Outcomes measured at three weeks revealed a -6.6 difference on the MADRS scale (p<0.001). Safety analysis indicated that COMP360 was generally well-tolerated, with most adverse events resolving quickly. The company anticipates starting a pivotal phase III trial in 2022.

COMPASS Pathways plc (Nasdaq: CMPS) announced the granting of its 10th patent, specifically US Patent No 11,180,517, which focuses on treatment-resistant depression (TRD) using crystalline psilocybin. With five patents in the US, the latest patent reinforces the company’s commitment to advancing mental health therapies. COMPASS's COMP360 formulation, recognized as a Breakthrough Therapy by the FDA, has shown statistically significant improvements in depressive symptoms in clinical trials. The company continues to expand its innovative approach to mental health care.

COMPASS Pathways (CMPS) reported positive topline results from its phase IIb trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD), indicating a rapid and sustained response from patients after a single 25mg dose. The company has also initiated a phase II study for PTSD and noted promising outcomes from an investigator-initiated study on cancer-related depression. Financially, COMPASS reported a net loss of $15.8 million for Q3 2021, with cash reserves of $294 million. The acquisition of an IP portfolio and new US patent for crystalline psilocybin were highlighted as advancements.

COMPASS Pathways plc (Nasdaq: CMPS) announced the successful results of its phase IIb clinical trial for COMP360 psilocybin therapy, targeting treatment-resistant depression (TRD). The trial involved 233 patients and achieved its primary endpoint, showing a statistically significant reduction in depressive symptoms with a 25mg dose compared to a 1mg dose, as indicated by a -6.6 points difference on the MADRS scale (p<0.001). The therapy was well tolerated, with over 90% of adverse events being mild or moderate. The company plans to initiate a pivotal phase III trial in 2022.